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ABSTRACT
Background: Th e prevalence and incidence of primary biliary cirrhosis 
(PBC) is increasing in the Western world. Th e highest prevalence, 402 per 
million, is reported in the USA and the highest incidence in Scotland, 
49 per million per year. Our aim was to assess the epidemiology of PBC in 
diff erent areas of Finland and to fi nd out whether the possible increase is 
related to better survival or increased incidence, or both. 
Th e treatment of PBC is based on Ursodeoxycholic acid (UDCA). All of 
the patients, however, do not receive biochemical and histological remission 
with this therapy. Our treatment option was to combine budesonide, 
a potent corticosteroid with a high fi rst pass metabolism in the liver, to 
UDCA and determine whether the suppression of infl ammation and 
fi brosis is achievable and for safety reasons investigate the bone eff ects and 
pharmacokinetics of budesonide in PBC patients.
Th e liver histology has been the only reliable way to assess and follow 
the stage and infl ammation grade of PBC. Our aim was to fi nd out if any 
laboratory test, or combination of tests, would serve as a surrogate marker 
for liver fi brosis or infl ammation. 
Patients and methods: Patients for the epidemiological study were 
searched from the hospital discharge records from year 1988 to 1999. Th e 
diagnosis was confi rmed from hospital case records, the place of recidence 
from the Population Information System, and the deaths from the National 
Causes of Death Register. Th e population examined represents over 56% of 
the Finnish population.
In the treatment study, 77 PBC patients at stage I to III were randomized 
from 3 university hospitals to receive budesonide 6 mg/day combined to 
UDCA 15 mg /kg/day or UDCA alone for three years. Th e liver histology, 
bone mass density (BMD) measurement, Doppler ultrasound of the 
liver, and upper endoscopy with bile acid sample from duodenum were 
performed prior the treatment and at the end of the study to confi rm 
the stage of the PBC and to fi nd out the effi  cacy and side-eff ects of the 
treatment. Biochemistry was obtained with every visit at four months 
intervalls. Th e pharmacokinetic study consisted of 22 patients whose 24 h 
bloodsamples were collected aft er ingestion of budesonide. Th e plasma 
budesonide concentrations were quantifi ed by liquid chromatography-
tandem mass spectrometry.
Sixty-nine paired biopsies were analyzed along with the patients 
routine biochemical markers, hyaluronic acid (HA), bile acids, cholesterol 
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precursors, plant sterols, and amino-terminal propeptide of type III 
procollagen (PIIINP) together with surrogate indexes: Forn’s index, 
AST/platelet ratio index (APRI), Fibrosis index, PBC score.
 
Results: Th e prevalence of PBC rose from 103 (CI 97 to110) to 180 
(172–189) per million from 1988 to 1999, an annual increase of 5.1%. 
Th e incidence rose from 12 (10 to 14) to 17 (15 to 20) accordingly, an 
annual increase of 3.5%. Th e age at dignosis remained stable (58–56 years), 
but the age at death increased markedly from 65 to 76. During the study 
period 53% of the deaths were liver related and 7% of them were due to 
hepatocellucar carcinoma. Th e risk of death, especially liver related deaths, 
dimished over time. Hazard ratios were 0.6 (0.4–0.9) and 0.4 (0.2–0.8) per 
10-year increment in time at PBC diagnosis.
Th e combination therapy with UDCA and budesonide was eff ective: 
stage improved 22%, fi brosis 25%, and infl ammation 32%. In the UDCA 
group the changes were: 20% deterioriation in stage and 70% in fi brosis, 
but a 10% improvement in infl ammation. Th e comparison between the 
treatment groups were statistically signifi cant for stage (p = 0.009) and 
fi brosis (p = 0.0009), but not for the infl ammation.
BMD in femoral neck decreased by 3.6% in the combination group 
(p = 0.0002) and by 1.9% in the UDCA group (p = 0.029). Th e reductions 
in lumbar spine were 2.8% (p = 0.003) and 0.7% (p = 0.25), accordingly. 
Th e changes in BMD between the groups were not statistically diff erent. 
Th e mean s-cortisol values became signifi cantly lower aft er two years in 
the combination group compared to the UDCA group, whereas the blood 
glucose levels did not diff er. 
Th e Cmax, AUC (0–24h), and t1/2 of budesonide did not diff er signifi cantly 
between the stages 0–I, II, and III, althougth the AUC (0–24h) seemed 
to be lower at stage 0. No statistically signifi cant correlations between the 
Cmax, AUC (0–24h) or t1/2 of budesonide, and change of histological stage 
and grade, bilirubin level or change of BMD were found.
In precirrhotic PBC HA, PIIINP, bile acids, and AST were signifi cantly 
diff erent within stages I–III and could diff erentiate the mild fi brosis (F0F1) 
from the moderate (F2F3). Th e combination of these individual markers 
(PBC-score) further improved the accuracy (p < 0.0001 in baseline stage, 
p < 0.001 in baseline fi brosis). Th e accuracy of APRI at baseline was 
somewhat lower in stages (p < 0.01) and in fi brosis (p < 0.05). Th e area 
under the ROC of the PBC score, using a cut of value 66, had a sensitivity 
of 81.4% and a specifi city of 65.2% to classify the stage of PBC. Previously 
reported scores did not reach signifi cance in AUROC.
Conclusions: Th e epidemiology of PBC in Finland follows the increasing 
trend of other western countries. Th e prevalence and incidence resemble 
data from other Nordic countries and do not rise as high as prevalence 
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from USA and UK. Th e increasing prevalence in Finland is due to both 
increasing incidence and improved survival. 
Th e combination of budesonide and UDCA improves liver histology 
compared toUDCA in non-cirrhotic stages of PBC. Th e treatment may 
lead to some systemic corticosteroid side-eff ects. Th e adrenal suppression 
and eff ects on bone has to be considered during the treatment. Th e 
pharmacokinetics of budesonide in diff erent non cirrhotic stages of PBC is 
equal, although they may diff er from the healthy liver. Th e budesonide and 
UDCA combination treatment is an option to those patients who do not 
receive full response from UDCA alone and are still at the non-cirrhotic 
stage of PBC.
 Hyaluronic acid, PIIINP, AST, and bile acids may serve as tools to 
monitor the treament response in the early stages of PBC. Combining these 
biomarkers in to a simple index potentiates their diagnostic value and gives 
possibilities of reducing repeated liver biopsies in patients’ follow up. 
233442_RAUTIAINEN_sisus_0612.indd   12 14.12.2007   7:17:28
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1 INTRODUCTION
Primary biliary cirrhosis (PBC) is an autoimmune liver disease of 
unknown ethiology. An infl ammation in the small intrahepatic bileducts 
leads to destruction of bile ducts, accumulation of toxic compounds in to 
the liver, and eventually to cirrhosis. Th e incidence and prevalence of PBC 
are increasing in the western world. Th e reasons for increasing prevalence 
might be the increasing exposure of diff erent chemicals in our everyday 
life, which may lead to the loss of tolerance in suspectible individuals. So 
far, there has been no epidemiological data of any cholestatic disease in 
Finland.
Th e treatment of PBC is based on administration of ursodeoxycholic 
acid (UDCA), which decreases infl ammation in early PBC. Despite UDCA 
treatment, in 20 years time, over 50% of patients will end up with cirrhosis 
if other causes do not limit survival. Multiple other drugs have been 
tested for PBC, but none of the immunomodulators, for example, have 
fulfi lled safety requirements nor shown enough eff ectiveness to become an 
additional drug of choice.  
Th is thesis aims to fi nd out the prevalence and incidence of PBC 
in Finland and the factors associated for the possible changes in the 
epidemiology of PBC.
Another aim was to fi nd out whether the budesonide, a corticosteroid 
with high fi rst pass metabolism, could stop the infl ammation in small 
bile ducts and become an additional therapy to PBC. Th e safety aspects, 
including cortisol and bone metabolism, together with pharmacokinetic 
parameters necessitate carefull investigation. Th e follow up of PBC has 
been based on the liver histology and our aim was to fi nd out surrogate 
markers to make the assessment of the disease easier and safer.
14
2 REVIEW OF THE LITERATURE
Primary biliary cirrhosis (PBC) is an autoimmune liver disease with 90% 
female predominance. It is characterized by destruction of the bile duct 
epithelial cells in the small intrahepatic bile ducts. Th e loss of bile ducts 
leads to accumulation of toxic substances within the liver, which causes 
hepatic damage, fi brosis, cirrhosis, and liver failure. Nowadays, 60% of 
patients are asymptomatic at presentation (1). In symptomatic patients, the 
most common complaints are fatigue 21% and itching 19% (2). 
2.1 Diagnosis and differential diagnosis
Th e diagnosis of PBC is based on the cholestatic serum enzyme pattern 
(elevated alkaline phosphatase), a compatible liver histology, and a high titer 
of antimitochondrial autoantibodies. Th e diagnosis is regarded defi nite if 
all three features exist and probable if two of them are present. Th e elevated 
IgM supports the diagnosis of PBC, but it is not always there.
2.1.1 Histology
Th e histology of PBC consists of damaged or destroyed small bile ducts 
(less than 70–80 μm) accompanied by surrounding infl ammation of the 
lymphocytes, plasma cells, eosinophils, and histiocytes. Granulomas may 
exist especially in the early phases of PBC. 
Th e histological appearences are divided to four stages: Stage I, 
infl ammation of portal triads; Stage II, reduced number of normal bile 
ducts and infl ammation extending from the portal triads to the surrounding 
parenchyma; Stage III, fi brous septa linking adjacent portal triads; and 
Stage IV, cirrhosis with regenerative nodules (161).  Changes in the liver 
are focal and diff erent stages may overlap. 
Th e infl ammation activity can be graded (0–3) by the METAVIR point 
score (162) which is based on the combination of lobular and interface 
infl ammation. Lobular infl ammation is graded: 0 = less than one focus, 1 = 
one focus per lobule and 2 = multiple foci per lobule or bridging necrosis. 
Interface infl ammation: 1 = focal in some portal areas, 2 = focal in most 
portal areas or diff use in some, 3 = diff use in all portal areas. 
2.1.2 Anti mitochondrial antibodies
Th e destruction of the bile duct epithelial cells in the small intrahepatic 
bile ducts is a T-cell mediated process. Th e targets of T-lymfocytes are 
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the dihydrolipoamine acetyltransferase components of the 2-oxo-acid-
dehydrogenases in the mitochondrial inner leaf. Pyruvate dehydrogenase is 
the best known of these antigens and its dihydrolipoamine acetyltransferase 
component is PDC-E2. Ninety percent of patients have positive 
antimitochondrial autoantibodies (AMA) against PDC-E2 (3). With more 
sensitive recombinant methods for detecting AMA, the proportion of AMA 
negative patients decreases to 5% (4). When detecting anti PDC-E2, anti 
brached –chain a-ketoacid dehydrogenase complex (BOADC-E2), and the 
2-oxoglutaric-dehydrogenase complex (2-OADC) of those initially AMA 
negative patients 20% are positive for one or more of these antigens (5). 
Th e titer of AMA does not predict the stage of PBC nor does it refl ect 
the eff ect on the treatment (6). Th e AMA negative PBC or autoimmune 
cholangitis (AIC) have the same disease features as PBC and they are 
usually antinuclear antibody (ANA) positive (5). Positive ANA are found 
in approximately 50% of PBC patients (7).
2.1.3 Differential diagnosis
Diff erential diagnosis within autoimmune liver diseases is not always 
possible because of their overlapping tendency. Th e PBC-autoimmune 
hepatitis (AIH) combination appears in 8% (8) to 9% (9) of the cases 
and in the latest report upto 13% (10). PBC and primary sclerosing 
cholangitis (PSC) overlapping is a much rarer occasion than overlapping 
with AIH, but overlapping occurs (11) and also coexistent PBC and PSC 
are reported (12). 
Other autoimmune conditions are common in PBC. In a study from 
UK, 53% of the patients had other autoimmune condition: Sjögren’s 
syndrome 25%, autoimmune thyroid disease 23%, rheumatoid arthritis 
17%, scleroderma 8%, Raynaud’s phenomenon 24%, systemic lupus 
erythematosus (SLE) 1%, autoimmune thrombocytopenic purpura 1%, 
and pernicious anemia 4% (13). 
2.2 Pathogenesis
2.2.1 Genetics
Familial clustering and high concordance in monozygotic twins, 63%, 
suggests PBC has a genetic component (14). Th e number of family 
members having PBC varies from 2.4% to 7.1% in studies published 
aft er 1990 (15). In a study from the UK the relative risk for a sibling of an 
aff ected individual to be diagnosed with PBC was 10.5 (16). A 1/10 female 
predominance exists, the reason for this is not completely understood. 
Women with PBC, however, have an increased prevalence for monosomy X 
in periferial white blood cells (17). Th e loss of the X chromosome increases 
with age, which may explain the late onset of disease (17). Genes involved 
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in immunological tolerance are located in the X chromosome and loss of 
these genes may predispose to the breakdown of self-tolerance and to the 
development of autoimmune diseases (18). Microchimerism does not have 
role in PBC (18).
Despite eff orts, consistent associations between PBC and HLA 
alleles have been diffi  cult to fi nd (15). From the non-MCH genes single 
nucleotide polymorfi sms of 1,25–dihydroxyvitamin D receptor (VDR) and 
cytotoxic T lymphocyte antigen-4 (CTLA-4) have been implicated in PBC 
susceptibility. Th e association between HLA class I molecules and PBC 
seems weak, but some association for HLA-B alleles are found (19).
HLA class II association, HLA-DRB1*0801, for PBC is found in 
caucasians in USA and in Europe (20–24). Some European studies also 
suggested an association with DR3 and DPB1’0301 (25–27). Th e protective 
eff ect of the DRB1*11 allele against PBC was found in Italian population 
(28,24) and DRB1*13 in Italian and UK patients (24). HLA class II 
involvement in PBC is complex and the HLA-II background might follow 
a geographical pattern (15).
Th e genes of the MCH class III region include tumor necrosis factor alfa. 
Data from association studies for PBC are confl icting (29). A polymorphism 
of the gene promoter region more frequently produces variant the TNF1 
and seldom TNF2, the latter is associated with increased transcription. It 
has been suggested that TNF2 allelele would be protective against onset of 
PBC (30), but many studies have not been able to confi rm this, nor fi nd any 
association with TNF1/TNF2 and severity of PBC (15).
Single nucleotide polymorfi sms of the 1.25–dihydroxyvitamin D receptor 
(VDR) gene is associated with PBC multiple studies (15). Th e VDR gene 
determines immunomodulatory activity of vitamin D. Its association with 
accelerated bone loss in cholestasis is suggested (31), but not confi rmed 
(32). Certain alleles of VDR might explain the low prevalence of PBC in 
black women and theoretically exposure to sunlight may have a role in 
PBC (15).
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is expressed by T cells 
when regulating periferial T cell responses. Polymorfi sm is associated with 
PBC in England and in China (33–34).
2.2.2 Enviromental factors
Th e suspected mechanism for initiation of autoimmunity in PBC is 
molecular mimicry between microbial agents and self antigens (35). 
Enviromental chemicals are metabolized primarily in the liver. Th e possible 
mechanisms of xenobiotics include direct toxic eff ect leading to abnormal 
cell death by apoptosis or necrosis, which may generate immunogenic 
auto-epitopes. Other mechanisms suggest that neoantigen-specifi c primed 
T and B cells crossreact with less immunogenic native autoantigen and/or 
chemical modifi cation of the native cellular protein lead to presentation of 
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cryptic peptides (36). Environmental factors like retroviruses, chemicals 
(37), and bacteria for example Eschericia coli (38) have been suggested as 
causative agents. Th e latest and the strongest candicate for immunological 
trigger is Novosphingobium aromaticivorans, which has a close homology 
with human PDC-E2. Novosphingobium aromaticivorans is a gram 
negative aerobic bacterium found worldwide in soil, water, and coastal plain 
sediments (39). It can metabolize chemical compounds that are similar to 
xenobiotics, which are reactive against sera from PBC patients (37). Th us, 
N. aromaticivorans can break down self-tolerance by molecular mimicry 
due to subclinical infection and by metabolism of xenobiotics. In the initial 
study from Italy, 100% of the sera of AMA positive (anti PDC-E2), 33% 
of anti-brached–chain a-ketoacid dehydrogenase complex (BOADC E2) 
positive, and even 12% of AMA negative PBC patients reacted against 
proteins from N. aromaticivorans. None of the control sera reacted against 
N. aromaticivorans. Twenty-fi ve percent of the PBC patients and 25% of 
the controls had N. aromaticivorans in their feces (40). Th e fi nding was 
confi rmed in the Icelandic population (41). 
In a questionnaire based study in the USA smoking, tonsillectomy, and 
vaginal or urinary tract infections in females were associated with PBC 
compared with controls (42). Th is fi nding was confi rmed with a larger 
interview based study from USA. Th e history of urinary tract infections, 
past smoking, and use of hormone replacement therapy were risk factors 
for PBC and slight association for use of nail polish was found (43). 
Smoking, urinary tract infections, itching at pregnancy, and dyed hair were 
risk factors for PBC in a questionnaire study from the UK (44). Cigarette 
smoke contains benzene, which is one of the volatile compounds found 
in super fund toxic waste sites (SFS). Living near these places increases 
the probability of ending up with a liver transplantation because of PBC. 
Chemical compounds may trigger autoimmunity and increase the risk for 
PBC or enhance the progression of PBC (45). 
Common chemical reagents, aromatic and halogenated hydrocarbons 
may lead to autoantigen modifi cations and enhance autoantibody reactivity 
as well. For example 2-octunoid acid, widely used in the environment 
including perfumes, lipsticks, and many food fl avorings, was found to 
modify PDC-E2 (46) and may perhaps be one of the explaining factors for 
female predominance of PBC. 
2.3 Epidemiology 
PBC mostly aff ects women in industrialized countries and the fi rst 
epidemiological data on PBC were published 1974 (47), since that over 
forty epidemiological studies, mainly from industrialized countries, have 
been published. Many of the studies, especially those published before 1986, 
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are of low quality (48). Th e sample sizes, case fi nding methods, diagnostic 
criteria, and reference populations vary greatly, which make it diffi  cult to 
compare prevalence and incidence data in diff erent studies.  Prince M (48) 
has collected data in to a review article from epidemiological studies until 
2001. In data before 1986 the highest incidence was found in Sweden, 13.7 
per million per year (49,50), and the lowest in England and Wales, 0.6 per 
million per year (47). Th e highest prevalence was found in Sweden, 128 per 
million (50), and the lowest in Spain, 11.1 per million (51). 
Th e epidemiologial studies published from 1986 to 2002 are summarized 
in the fi gures 1 and 2. Th e highest prevalence among the whole population 
is reported from Olmsted county, Minnesota, in the USA, a prevalence 
of 402 per million (52). In Europe, the highest prevalences come from 
the UK, 379 per million in Scotland (53) and 251 in Newcastle, England 
(54). In northern Europe, epidemiological data on prevalence of PBC exist 
from Sweden, Norway, and Estonia. Th e prevalence was 151 per million in 
Sweden (55), 146 in Norway (56), and 27 in Estonia (57).
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Figure 1. Point prevalence in order of year recorded. Values are obtained from a 
review article of Prince M & James OF 2003(48) until year the 2000 and aft er that from 
original articles. 
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Incidence rates of PBC are highest in the UK and USA, 49 per million per year 
in Scotland (53), 27 in Newcastle (54), and 27 in the USA (52). In Northern 
countries the incidence rates are 16 per million per year in Norway (56), 13 
in Sweden (55), 9 in Denmark (81), and 2 in Estonia (57).
Figure 2. Th e mean incidence of diff erent study periods in individual studies, the 
studies appear in order of the last year of survey. Values are obtained from a review 
article by Prince M & James OF 2003 (48) and aft er that from original articles.
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2.4 The natural history of PBC
2.4.1 The natural history
Before 1970’s the majority of the patients, 80%, were diagnosed when 
they were symptomatic (86) and most of them already had cirrhosis. In 
later years asymptomatic PBC patients were also diagnosed and their 
prognosis was better than that of those who had symptoms. It was also 
suggested that prognosis could be similar in age and sex matched control 
population (87). 
Nowadays, 60% of patients are asymptomatic at presentation (86). Th e 
untreated asymptomatic PBC patients tend to develop symptoms within 
four years and their survival is lower than survival of the healthy population 
(88). In the cohort of 279 untreated patients the median survival of 
asymptomatic patients was 16 years and 7.5 years for symptomatic patients 
(89). Of asymptomatic patients, 33% remained symptom free in a median 
follow-up of 12 years but, aft er symptoms developed, the survival rates 
were similar to symptomatic patients. In a study of 91 patients followed 
up to 17 years confi rmed the shorter survival for asymptomatic patients 
compared with the healthy control population (90), but those patients who 
remained asymptomatic had a similar survival compared with a matched 
control population. In that study they could not identify any prognostic 
features to fi nd patients who would develop symptoms. A survival study of 
770 patients from Northeast England shows no benefi t for asymptomatic 
patients, 61% of patients were asymptomatic at diagnosis and their median 
survival was 9.6 years and survival for symptomatic patients was 8 years 
(91). Th e study is compromised of a high number of deaths in asymptomatic 
patients implicating non-hepatic causes of death and putting the age at 
diagnosis in a determining position. 
Th e histological progression is divided into four stages (I to IV) and 
the stages predict the survival. Th e data from 916 biopsy specimens from 
222 patients shows a histological progression during a median of 3 years of 
follow-up. From the patients presenting with stage I, 31% had developed 
cirrhosis in four years and of patients initially at stage II, 50% reached 
cirrhosis. Th e histology was stable in only 20% of patients and 2 % showed 
regression. Th e overall progression was one stage in every 1.5 years (92). A 
subgroup of patients who may develop profound cholestasis without portal 
hypertension or cirrhosis while protein synthesis is intact exists. Th ese 
patients are ductopenic, but their liver is not fi brotic (93).
Bleeding form esophageal varices is a strong prognostic marker. Th e 
histological stage and elevated serum bilirubin are positive predictors for 
development of varices. Once varices have developed the 1 and 3 years 
survival rates are 83% and 59%, if bleeding has occurred the survival rates 
decrease to 65% and 46% (21). On the other hand, the varices may also 
be the fi rst marker of disease progression; the development of varices in 





























































Yale, 1983 (87) x x x           x 
European, 1985 (100) x x x        x  x  
Mayo, 1989 (99) x  x       x x x   
Forns’ score, 2002 (101) x    x   x x      
APRI, 2003 (102)    x     x      
Fibrosis index, 2004 (103)   x    x        
Ast/alt, 2006 (104)    x  x         
Hepatobiliary malignancies, mainly hepatocellular carcinoma (HCC), 
aff ect patients with PBC. Th e relative risk was 46 in women and 55 in 
men in a retrospective analysis from the Mayo clinic (95). Th e probability 
of HCC in patients at stages III and IV PBC was similar to hepatitis C 
cirrhosis, but lower at earlier stages in a Spanish study (96). In a Japanese 
study this fi nding was confi rmed and they reported a 7.7% cumulative 
appearance of HCC in 10 years at early stages and 12.3% advanced stages 
(97). Risk factors for HCC were age at the time of diagnosis, male gender, 
and a history of blood transfusions. In addition to these risk factors signs 
of portal hypertension and cirrhosis were associated with HCC in a study 
from Mayo clinic (98).
2.4.2 Prognostic models and serological markers for 
 monitoring PBC
Th ree prognostic models of PBC are presented in Table 1. Th e Mayo model 
is based on 418 untreated patients and its advantage compared with two 
other models is its independence of liver histology. Th e major determinant 
of the Mayo model is bilirubin and the four other independent prognostic 
variables are patient’s age, serum albumin, prothrombin time, and the 
severity of fl uid retention (99). It is useful in predicting cirrhosis and the 
need for a liver transplantation, but in non-cirrhotic PBC patients with 
normal bilirubin values the Mayo model does not detect progression of 
the stage.
Table 1. Natural prognostic models in PBC and markers in liver fi brosis. (87,99–104) 
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In hepatitis C several non-invasive markers for evaluating fi bosis have 
successfully been introduced, for example Forn’s score (101) and the 
AST/platelet ratio index (APRI) (102). In PBC the ALT/AST-ratio (104) 
and the sum of bilirubin and hyaluronic acid (Fibrosis index) (103) have 
recently showed some diagnostic value for detection of fi brosis, but not for 
lymphocytic piecemeal necrosis, previously shown to be associated with 
the risk of cirrhosis (105). 
From serum non-cholesterol sterols, S-cholestanol, a 5α-saturated 
derivate of cholesterol, has previously been shown to correlate closely with 
S-bilirubin and with the histological stage of primary biliary cirrhosis (106). 
Both intestinal absorption and biliary excretion of sito- and campesterols 
are regulated by ABCG5/8-transporters (107, 108) and the excretion of 
plants sterols are impaired in cholestasis, especially that of sitosterol (109). 
Th erefore, non-cholesterol sterols and serum campe/sitosterol ratio have 
been suggested to serve as sensitive markers for developing cholestasis and 
the progression of PBC.
2.5 Treatment
2.5.1 Medical treatment
2.5.1.1 Ursodeoxycholic acid (UDCA)
UDCA is hydrophilic tertiary bile acid, a 7 beta-epimer of chenodeoxycholic 
acid. UDCA constitutes only 1 to 3 per cent of biliary bile acids in man. 
In cholestasis, bile accumulates in the liver and the hydrophilic UDCA 
is less hepatotoxic than the more hydrophobic primary bile acids 
chenodeoxycholic acid and cholic acid.
Oral administration of UDCA 10–15 mg/kg/day leads to UDCA 
becoming a predominant circulating bile acid (40–60%), while the amount 
of cholic acid, chenodeoxycholic acid, and 3-beta –hydroxy-5 chenolenoic 
acid decrease (110).
Mechanisms of action of UDCA are multiple aiming at one or more 
pathogenetic processes in cholestasis. UDCA protects cholangiocytes 
against toxic eff ects of hydrophobic primary bile acids. Th e membrane 
protective eff ect is mainly at the bile duct level, where the bile acid 
concentrations are high. Th is eff ect is apparent in liver histology, where the 
portal infl ammatory reaction is less severe in UDCA treated PBC patients 
than in placebo treated patients (111). Th e enhancement of impaired 
biliary secretion caused by UDCA, results from the stimulating expression 
of transporter proteins in the liver and insertion of transporter molecules 
into the canalicular membrane at transcriptional and posttranscriptional 
level (112,113). Th ese mechanisms also increase the elimination of 
toxic biliary compounds. Th e antiapoptotic mechamisms of UDCA are 
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associated with a reduction of the mitochondrial membrane permeability 
transition and the mitochondrial cytocrome c release (114). UDCA has 
immunomodulating actions and it reduces the expression of HLA (MCH) 
class 1 antigenes in cholestatasis (115).
Over 20 randomized placebo controlled studies evaluating the 
eff ect of UDCA on liver histology, laboratory values, survival, and liver 
transplantation exist. Th e Cochrane review evaluated 16 randomized 
studies (116). Th e positive eff ect was seen in liver biochemistry, the eff ect 
on liver histology was not clear, no benefi t on mortality, although, the 
incidence of liver transplantations decreased. Aft er the Cohrane analysis a 
combined analysis of four studies showed the benefi t of UDCA on periportal 
necroinfl ammation, ductular proliferation, and stage progression in patients 
with early stages, I and II, of PBC, but no benefi t could be shown if patients 
of all stages were regarded (117). Th e survival benefi t is diffi  cult to show 
in short treatment studies, therefore the meta-analyze from China (118) 
included only randomized studies over a two years duration with UDCA, 
a dose of 10 to 20 mg/kg/day. Th ey found seven suitable trials and a meta-
analyze of them showed a reduction of the need for liver transplantations 
and a marginal reduction in liver transplantations or death combined, 
but there were no eff ect on death alone with UDCA use. Th e latest (119) 
clinical review and meta-analysis of 16 randomized trials (1447 patients) 
found positive eff ect of UDCA only to bilirubin, ascites and jaundice, 
but they could not fi nd signifi cant benefi t to mortality, mortality or liver 
transplantation combined,  liver histology, pruritus, fatigue, autoimmune 
conditions, or to portal pressure. Short studies and the more severe stage of 
PBC were associated with a better eff ect of UDCA (119). Th ese fi ndings are 
controversial to the previous knowledge of the eff ect of UDCA.
Normalization of survival of patients with early stage PBC using UDCA 
was shown in a French study using multistate Markov model. Th e survival 
was equal compared to normal controls and signifi cantly improved 
compared with predictive values of the Mayo risk score (120). Th is fi nding 
was confi rmed with Dutch PBC patients using UDCA compared to Dutch 
controls. Patients with a normal serum albumin and bilirubin levels had 
similar life expectancy as the control population, but if albumin, bilirubin, 
or both were impaired, then the survival rates were decreased (121). Also 
in the Spanish study the patients with full biochemical response to UDCA 
had a similar prognosis as the control population. Th e survival was superior 
to the predictive Mayo score survival (122). 
UDCA treatment is the only current medication for PBC accepted by 
the FDA. Its eff ect has been proved in the early stages of PBC (117), though 
current meta-analysis did not confi rm this fi nding (119). UDCA, however, 
does not suppress infl ammation for all of the patients. In 20 years, over 
50% of the patients who were initially at stages I or II had progressed to 
stages III–IV or required a liver transplantation (120), at least those UDCA 
nonresponders are the patients who need combination therapies.
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2.5.1.2 Prednisolone
Th e suppression of infl ammation in the portal tracts with glucocorticoids 
is a tempting therapeutic possibility. Altogether three studies of PBC with 
prednisolone exist (Table 2) and in all of them a positive eff ect on liver 
histology was found (123–125), but the threat of bone loss has limited its 
use. In a study with prednisolone (30 mg/day tapered to 10 mg/day), the 
bone mass density (BMD) decreased almost twice as much as expected 
in one year (123). In a study with a longer duration the decrease in BMD 
was consistently greater up to three years in the predisolone group than in 
the control group, but a statistically signifi cant diff erence was only found 
aft er the fi rst year (124). In Leuschners study (125), the BMD markedly 
decreased in one patient, in others the reduction was not signifi cant. 
 2.5.1.3 Budesonide
Budesonide is a non-halogenated glucocorticoid, and unlike prenisolone, 
about 90% of its oral dose is metabolized presystemically in healthy 
individuals (127). Budesonide is metabolized in the intestinal wall and 
liver by cytochrome P450 3A into two major metabolites, 16α-hydroxy-
prednisolone and 6β-hydroxy-budesonide. Th e glucocorticoid activity of 
these metabolites is only 1% to 10% of that of budesonide (127). Compared 
to prednisolone, the glucocorticoid receptor binding affi  nity of budesonide 
is 15 to 20 times higher, and it has been suggested that its eff ect on liver 
infl ammation may be greater (128–130). 
In PBC, budesonide 9 mg/day given together with UDCA for two years 
had a positive eff ect on liver histology in non-cirrhotic PBC patients without 
a signifi cantly deleterious eff ect on the BMD of the lumbar spine (LS) (126) 
Table 2. Glucocorticoids in PBC. 
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(Table 2). In another study, which also included also patients with cirrhosis, 
budesonide 9 mg/day combined with UDCA had a signifi cantly positive 
eff ect on bilirubin and alkaline phosphatase (ALP) levels, but resulted in a 
worsening of osteoporosis and hyperglycemia and an increase in the Mayo 
Risk Score, eff ects on histology were not evaluated (131).
2.5.1.4 Other mediactions
Th e immunosuppressive medications have been rather disappointing in 
PBC. One study of azathioprine in combination with prednisolone and 
UDCA exists. It was eff ective in one year of therapy in those patients who 
did not achieve full response to UDCA (132). Colchicine with its anti-
infl ammatory and antifi brotic eff ects has a slight additional eff ect in some 
patients when added to UDCA in early PBC (133), but not in advanced 
PBC (134). Meta-analyses of colchicine have not confi rmed its eff ect (135). 
Th e UDCA combination with methotrexate was not eff ective (136).  Th e 
other medications such as mycophenolate mofetil, cyclosporine, silymarin, 
simvastatin, sulindac, bezafi brate, and fenofi brate have mostly been studied 
in single studies with no proven effi  cacy to PBC (35).
2.5.2 Special features
2.5.2.1 Osteoporosis of PBC
Osteoporosis is the primary metabolic bone disease in PBC, although the 
potential for osteomalacia exists. Th e metabolism of vitamin D is normal, 
but malabsorption of calcium and vitamin D may occur (137). Th e 
prevalence of osteoporosis and/or osteopenia in PBC are controversial. 
Some studies fi nd the association with BMD and PBC and the severity of 
liver disease (138,139) and others only with age and postmenopausal status 
(137,140). Th e population cohort study from Nottingham found a 2-fold 
relative increase in any fracture in PBC patients compared with age and 
sex-matched control population (141).
Th e treatment of postmenopausal osteoporosis with estrogens is 
eff ective (142, 143) and had not resulted is worsening of cholestasis (142). 
Bisphosphonates, especially alendronate, are also eff ective on osteoporosis 
in PBC patients and their safety is good, (144,145) although long-term 
safety data does not exist.
2.5.2.2 Pruritus
Th e etiology of pruritus in PBC is unknown, but the symptom is common, 
19% of patients already suff er from it at PBC presentation (2). Bile acids 
are suspected to mediate the pruritus in cholestasis, however, the plasma 
concentrations of bile acids do not correlate with pruritus. Th e possible 
substances circulating in the plasma in cholestasis, which could mediate 
pruritus, have not been found. Resins, cholestyramine and cholestipol may 
relieve pruritus, but they interfere with other medications and are not very 
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eff ective. Mechanisms of rifambicin are unknown, but it is helpful to some 
patients. Th e eff ects of antihistamines are weak and they only suit  mild 
pruritus. (2,35).
Plasma separation and anion absorption decreases pruritus, but the 
eff ect is transient (146).
Th e opioidergic system and serotonin neurotransmitter system may 
be involved in pruritus on cholestasis. Th e opioid antagonists naloxone 
and naltrexone are eff ective in some patients (35). A recent study with 
serotonin uptake inhibitor sertraline, 75–100 mg/day, showed a marked 
improvement in pruritus compared with a placebo (147).
2.5.2.3 Fatigue
Fatigue is the most common symptom at presentation of PBC (2) and it 
appears to be a very stable phenomenom (148). Fatigue in PBC is due to 
central nervous system (CNS) processes impaired by a combination of 
cholestasis and infl ammation. Morphological abnormalities of the CNS 
are found secondary to accumulation of manganese (149). Th e impaired 
circadian rhythm, abnormal nighttime sleep, and sleepiness in daytime 
result to fatigue (150). Modafi nil, a CNS-active agent, previously used 
for narcolepsia, obstructive sleep apnea, and shift -work sleep disorders, 
has shown to improve fatigue in PBC patients (151). Th e mechanisms of 
modafi nil on fatigue may not only result from direct CNS eff ects, but also 
the eff ects on the autonomic nervous system and blood pressure regulation 
may be involved (152,153).
2.5.2.4 Hyperlipidemia
Th e reduction of bile acid secretion in cholestasis leads to diminished bile 
acid synthesis and a down-regulation of hepatic cholesterol synthesis. Th e 
hepatic injury causes decline in functional LDL receptors and thus, the 
increase in total blood cholesterol, mainly LDL that has not been cleared 
by hepatocytes (154). Th e elevated LDL is mainly LP-X, an abnormal 
LDL particle, which has antiatherogenic properties and may reduce the 
atherosclerotic risk (155). In a study, where hypercholesterolemic PBC 
patients were compared with hypercholesterolemic non-PBC patients 
and normocholesterolemic patients, the risk for thickening of the intima 
in the carotic artery was only present in hypercholesterolemic non-PBC 
patients (156). Th e Dutch 14-year retrospective analysis demonstrated 
a 12% cardiovascular death rate in PBC patients (157). Th us, the 
need for cholesterol lowering agents depends on the other risk factors 
for atherosclerosis (155, 156). Th e intestinal cholesterol absorption 
is reduced in PBC and it is related to decreased bile acid synthesis, 
resulting in poor micellar solubilization (154). Th erefore cholesterol 
absorption inhibitors, such as ezetimibe, may be an ineff ective treatment 
for hypercholesterolemia. Statins as cholesterol lowering agents seem 
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to be safe when monitored carefully, though lovastatin, simvastatin, 
atrovastatin, and rosuvastatin are excreted in bile. In cholestasis statins 
may accumulate at toxic levels (155).
5.2.3 Liver transplantation
In end stage liver disease the liver transplantation is a good option. In 
Finland, PBC has been the primary cause of liver transplantation, but 
recently the need for transplantations in other liver diseases has increased. 
Th e indications for liver transplation in Finland are equal to other Nordic 
countries and consist of intractable pruritus or fatigue, relapsing bleeding 
from esophageal varices, refractory ascites or spontaneous bacterial 
peritonitis, hepatic encephalopathy, malnutrition, hepatocellular carcinoma, 
hepatopulmonal syndrome, or a serum bilirubin over 170 μmol/L and 
serum albumin under 25 g/L. Th e survival aft er transplantation in PBC 
is among the highest of all causes of liver transplantation. Survival aft er 
liver transplantation at 1, 5, and 10 years was 82%, 75%, and 61% in the 
Birgmingham transplantion unit (158). Th e recurrence of PBC in allograft  
was found histologically in 17% of patients aft er 3 years, but it did not 
aff ect the graft  survival (158). In a meta-analysis, the recurrence of the 
PBC in the allograft  was 18 % (159). No association was found to primary 
immunosuppression. In a German study the histological recurrence rate 
was 14% aft er 5 years and they found an association with recurrence to the 
use of tacrolimus as immunosuppressant (160). Two patients out of 14 with 
recurrence developed graft  dysfunction. Th e survival in German patients 
at 5, 10, and 15 years was 87%, 84%, and 82%.
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3 AIMS OF THE STUDY
Th e aims of the present study were to 
examine the epidemiology of primary biliary cirrhosis in Finland and 1. 
to evaluate whether the possible increase in prevalence was attributable 
to the increasing incidence, better survival, or both.
fi nd out whether budesonide in combination with UDCA is an eff ective 2. 
treatment on liver histology and laboratory markers of PBC compared 
with UDCA alone.
study the steady-state pharmacokinetics of budesonide and the bone 3. 
mass density eff ects of 3-years of treatment with budesonide and 
UDCA, compared to UDCA alone, in patients with precirrhotic PBC 
and to relate the pharmacokinetics of budesonide to the stage of liver 
histology.
fi nd out non-invasive serological markers to evaluate liver infl ammation 4. 
and fi brosis and  the  progression of PBC.
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4 PATIENTS AND METHODS
4.1 Patients and methods in epidemiological study
4.1.1 Case Defi nitions
Th e diagnosis of PBC was defi nite if all three of the following criteria 
were fulfi lled: constantly elevated alkaline phosphatase, elevated 
antimitochondrial antibodies, and diagnostic or compatible liver 
histology. 
Diagnosis was probable if only two of those three criteria were present.
Incidence and prevalence rates include both defi nitive and probable cases.
4.1.2 Date of Diagnosis
Th e date of diagnosis was the earliest date at which a patient fulfi lled 
diagnostic criteria. 
4.1.3 Study Population
Patients were identifi ed from four university hospitals (Helsinki, Turku, 
Tampere, and Oulu), their regional hospitals, and private medical centers 
in these areas. Th ese areas cover southern, western, central, and northern 
parts of Finland (Study I, Figure1). Th e population of these study areas 
increased from 2 781 075 to 2 972 189 during the years 1988 to1999, which 
represents 56.3% and 57.5% of the total Finnish population for these 
years.
Each Finnish resident has a unique personal identifi cation code, which 
was used to locate their place of residence at the Population Information 
System maintained by the National Population Registry. Th e register system 
is updated online. Each patient’s place of residence was confi rmed annually 
(December, 31) during the study period from these registers. 
4.1.4 Study Period
Th e case fi nding period started in January 1, 1988 and ended in December 
31, 1999. Incidence rates of new diagnosis of PBC per million inhabitants 
were calculated from January 1 to December 31 each year, and the 
prevalence rates for the annual mean population accordingly.
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4.1.5 Case Finding Methods
Case fi nding methods: 1) A search for PBC was made from 25 hospitals 
discharge data regarding internal medicine or gastroenterology admission 
episodes, both the main diagnosis and additional diagnoses were recorded. 
Diagnosis codes 5716A, K74.3 (PBC) and 5716X, K74.5 (Biliary cirrhosis) 
were taken for further review. 2) A search from the archives of pathology 
departments for biliary cirrhosis. 3) Requests went to gastroenterologists 
in private clinics to identify PBC patients under their care. 4) A search of 
hospital discharge data was made in the Finnish Transplantation Unit, which 
serves all of Finland. Th e total amount of PBC liver transplantations from 
Finland are reported, as well as transplantations of the study population.
4.1.6 Data Collection
Hospital case records were reviewed in order to confi rm the diagnosis, no 
data on disease severity or course was registered. 
4.1.7 Deaths 
Th e survival of patients until 31 st of October 2004 was identifi ed by record 
linkage of the study data with the National Causes of Death Register 
maintained by Statistics Finland, with date and underlying cause of death 
extracted from this register. Causes of death are coded according to the 
ICD-9 and ICD-10.
4.1.8 Statistics
Prevalence and incidence rates were expressed per million persons per year 
and age- standardized according to the direct method using the European 
standard population (65). Annual population counts for the denominators 
came from the National Population Information System, which is updated 
continuously. Th e trends in prevalence and incidence were determined by 
log-linear Poisson regression models with year as an independent variable. 
Th e regression coeffi  cient of the year multiplied by 100 gives the average 
annual change in percentages. Th e 95% confi dence intervals (CI) of the 
trend estimates were calculated from the standard error of the regression 
coeffi  cient. Prevalence and incidence rates in the fi rst and the last year of 
the study are reported as smoothed with the Poisson regression model to 
avoid the eff ects of random fl uctuations. Factors related to survival aft er the 
PBC diagnosis were examined by Cox’s proportional hazards regression 
analyses. Statistical analyses were carried out with SAS (SAS institute 
1999). Ethical approval was obtained from the Ethics Committee of the 
Helsinki University Central Hospital. 
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4.2 Patients and methods in the treatment study 
4.2.1 Patients
PBC stage I to III patients were collected from university hospital districts 
in three cities in Finland (Helsinki, Tampere, and Turku). A study 
information letter was sent to internists and gastroenterologists at local 
hospitals to recruit PBC patients to the trial. Consecutive patients were 
enrolled into the study, if inclusion and exclusion criteria were met. Before 
study entry and randomization, the diagnosis and severity of PBC was 
confi rmed serologically (antimitochondrial antibodies S-AMA over 100 
units (normal <50) and elevated serum alkaline phosphatase >300 U/l 
(normal <275 U/l)) and determined by a recent (within 12 months) liver 
biopsy. (Baseline data Table 3)
 Group A
Budesonide + UDCA 
Group B  
UDCA
Number (male) 41 (5) 36 (4) 
Age mean (range) 52.6 (33-67) 54.2 (25-70) 
BMI kg/m2  mean (range) 24.8 (18-38) 25.7 (20-30) 
Previous treatment with UDCA 32 28
Stage I (%) 13 (17) 13 (17) 
Stage II (%) 10 (13) 16 (21) 
Stage III (%) 18 (23) 7 (9) 
Grade 0 11 5 
Grade I 14 15 
Grade II 10 10 
Grade III 6 6
Fibrosis 0 13 13
Fibrosis I 11 16
Fibrosis II 11 6 
Fibrosis III 6 1 
Table 3. Baseline data of 77 randomized patients. 
4.2.2 Exclusion criteria
Cirrhotic liver, stage IV
- Esophageal varices
- Portal or hepatic veins and arteries thrombosis, or reversed portal fl ow, 
or collaterals.
Age <18 or >70 years
Pregnancy or inadequate contraceptive use
Systemic use of corticosteroids or immunosuppressive medication
Clinically signifi cant concomitant liver disease or positive hepatitis-B-
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muscle antibodies (SMA), and liver-kidney-microsomal antibodies 
(LKM).
4.2.3 Study protocol
Th e study design was randomized but open, because a placebo for 
budesonide was not available. Th e study endpoint was the change in liver 
histology. No washout period for patients receiving UDCA prior the study 
existed. 
Randomization was done centrally at the Helsinki University Hospital 
with sealed envelopes in a block of ten and patients were stratifi ed according 
to previous UDCA use, and stages I–II and III according to the Ludvig 
criteria (161). (Figure 3, Study fl ow chart)
Figure 3. Study fl ow chart.
Upon study entry an esophago-gastro-duodenal endoscopy, Doppler 
ultrasound of the liver, bone mass density, liver biopsy (if not perfomed 
within 12 months), and a physical examination were performed and a 
complete medical history revealed.
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At 4-month intervals, each patient had a physical examination and the 
following laboratory tests were measured: Alkaline phosphatase (ALP), 
γ-glutamyltranspeptidase (GT),  alanine aminotransferase (ALT), bilirubin 
(bil), bile acids, albumin, prealbumin, prothrombin time, hemoglobin, 
leucocytes, platelets, erythrocyte sedimentation rate (ERS), plasma cortisol 
level, and fasting blood glucose (fb -gluc).
Th e following laboratory tests were made at 12-month intervals: amino-
terminal propeptide of type III procollagen (S-PIIINP), vitamin-D 
(S-25(OH)D3), immunoglobulin M (IgM), and immunoglobulin G (IgG). 
At the beginning and end of the study, serum-asetyltransferase (S-AST), 
s-hyaluronic acid (S-HA), urinary -N-telopeptide-collagen (U-NTX), 
plasma parathyroid hormone S-PTH, S-HbsAg, S-HCV-ab, S-AMA, 
S-SMA, S-LKM-antibodies, and antinuclear antibodies (S-ANA) were 
screened for. 
Aft er 3 years of therapy a liver biopsy, upper endoscopy, Doppler ultrasound 
of the liver were performed, BMD measured, and venous blood samples 
were collected for pharmacological measurements of budesonide.
4.2.4 Study medication
Group A) UDCA 15 mg/kg/day (divided into two doses; Adursal® 150 
mg tablets, LeirasFinland, Finland) and budesonide 6 mg/day (single 
morning dose: 2 Entocort® 3 mg depot capsules, AstraZeneca, Finland) 
Group B) UDCA 15 mg/kg/day. 
4.2.5 Other medications/ concomitant diseases
All patients with inadequate dietary calcium or vitamin D intake were 
advised to use a supplementation therapy (calcium 1000 mg /day and 
vitamin D 400 units/day minimum), but the medication used was not 
controlled. Two patients were on thyroxin replacement therapy for primary 
hypothyreosis and were euthyreotic. None of the patients had medication 
for epilepsy, nor did any of them have parathyroid disturbances or other 
metabolic bone diseases. One patient with celiac disease was on a gluten-
free diet. 
4.2.6 Histological evaluation
Liver biopsies were evaluated by a single pathologist, who was blinded 
to the clinical data and biopsy sequence. Ludwig criteria (161) was 
used to analyze the stage (I = portal hepatitis, II = periportal hepatitis, 
III = bridging necrosis or fi brosis or both, IV = cirrhosis). Th e METAVIR 
point score (162) to evaluate infl ammation activity from 0 to 3, which is 
based on lobular and interface infl ammation. Lobular infl ammation is 
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graded: 0 = less than one focus, 1 = one focus per lobule, and 2 = multiple 
foci per lobule or bridging necrosis. Interface infl ammation or lymphocytic 
piecemeal necrosis is graded: 1 = focal in some portal areas, 2 = focal in 
most portal areas or diff use in some, 3 = diff use in all portal areas. 
Th e METAVIR point score (162) was also used to assess fi brosis: 0 = normal, 
1 = portal expansion, 2 = porto-portal septa formation, 3 = porto-central 
septa formation, and 4 = cirrhosis. Stainings were at least hematoxylin-eosin 
for infl ammation and van Gieson or Herovici for fi brosis.
4.2.7 Bone mass density 
Th e BMDs were examined by dual-energy absorptiometry (DEXA) 
densitometers, i.e. with Lunar Prodigy (GE Lunar Corporation, Madison, 
USA) in the Tampere University Central Hospital, with Hologic QDR-1000 
(Waltham, MA, USA) in the Helsinki University Central Hospital, and 
with Hologic QDR- 4500C in the Turku University Central Hospital. BMD 
values were obtained from the lumbar vertebrae L1-L4 and the femoral 
neck. Th e T-score values at baseline, and the individual changes in BMD 
from the baseline to the study end were used in statistical analysis.
4.2.8 Questionnaire
All patients completed a questionnaire containing 41 questions about 
lifestyle factors aff ecting bone mass density and 11 additional questions for 
women concerning hormonal factors and medications. Coff ee and alcohol 
use, smoking, exercise, use of calcium and vitamin–D supplementation, 
diuretics, herbal medication, use of corticosteroids and anabolic steroids, 
fractures, other diseases and their treatments, use of milk products, 
exposure to sunlight, and for women time of menarche and menopause, 
contraception, pregnancies, ovarian operation, and estrogen replacement 
therapy were covered.
4.2.9 Pharmacokinetic measurements of budesonide
Aft er an overnight fast, a single dose of 6 mg budesonide (2 Entocort® 3 mg 
depot capsules, AstraZeneca, Finland) was ingested at 8 am, and venous 
blood samples were collected at 0, 3, 6, 8, 10, 16, and 24 hours postdose into 
tubes containing ethylenediaminetetraacetic acid (EDTA). Th e patients 
fasted for at least four hours aft er the administration of budesonide. 
Aft er sampling, plasma was separated and stored at -80°C until analysis. 
Plasma budesonide and cortisol concentrations were quantifi ed by liquid 
chromatography-tandem mass spectrometry, as described earlier (163). 
Th e quantifi cation limit for budesonide was 0.05 ng/mL and the day-to-day 
coeffi  cient of variation (CV) was 11% at 0.05 ng/mL, 6.4% at 0.4 ng/mL, 
and 3.6% at 2.0 ng/mL (n=5). Th e quantifi cation limit for cortisol was 
0.5 ng/mL, and the CV was 3.9% at 4.0 ng/mL, 5.9% at 24 ng/mL, and 2.5% 
at 120 ng/mL (n=5). 
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Th e pharmacokinetics of budesonide were characterized by the peak 
concentration (Cmax) in plasma, the time to Cmax (tmax), the area under the 
concentration-time curve from 0 to 24 hours [AUC(0-24h)], and elimination 
half-life (t½). Th e Cmax and tmax values were taken directly from the original 
data. Th e terminal log-linear part of each concentration-time curve was 
identifi ed visually, and the elimination rate constant (ke) was determined 
from the log-transformed data using the linear regression analysis. Th e 
t½ was calculated by the equation t½ = ln2/ke. Th e AUC(0-24h) values 
were calculated by use of the linear trapezoidal rule. All pharmacokinetic 
calculations were performed with the program MK-Model, version 5.0 
(Biosoft , Cambridge, UK).
4.2.10 Biochemical assessment
Serum concentrations of ALP, GT, ALT, AST, BIL, albumin, prealbumin, 
prothrombin time, hemoglobin, leucocytes, platelets, ERS, plasma 
cortisol level, and galactose elimination test were measured by standard 
laboratory methods. NTX excretion, osteocalcin, PTH, total cholesterol 
and triglyserides, and FB-GLUG were taken aft er an overnight fast. Th e 
NTX was measured in urine (fresh morning urine) by an enzyme-linked 
luminoimmunoassay, the PIIINP was measured by a radioimmunological 
assay from Orion Diagnostica (Espoo, Finland), HA by an enzyme-
linked binding protein assay (Corgenix, Tejon St. Westminster, USA), 
osteocalcin in serum by immunoradiometric assay, and PTH in plasma 
by immunochemiluminometric assay in a quality controlled laboratory. 
Total cholesterol and noncholesterol sterols in serum were measured 
from nonsaponifi able material by gas liquid chromatography (164,165). 
Noncholesterol sterols include cholestanol, cholesterol precursor sterols: 
Δ8-cholestenol, lathosterol, and desmosterol, and two plant sterols: 
campesterol and sitosterol. Th e data are expressed as mmol/mol of 
cholesterol (x102). 
4.2.11 Non-invasive scores
Various non-invasive scores derived from the laboratory data were 
calculated according to previously established criteria as follows:
Forn’s score = 7.811-3.131*ln(platelet count 109/l) + 0.781*ln(γGT U/l) 
+ 3.467*ln(age,y) -0.014*(cholesterol,g/l) (101). 
AST/platelet ratio index (APRI) = AST/ULN*100/platelet count, 
109/l (102). 
Fibrosis index = S-bilirubin [μmol/l]/14 + HA[μg/l]/143 (166). 
PBC score = HA[μg/l]+ PIIINP [μg/l]+ AST [U/l] + bile acids [mmol/l] ,
LnPBC-score = ln(AST) + ln(HA) + ln(PIIINP) + ln(BA). (PBC scores are 
not validated in literature before).
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4.2.12 Statistics
Th e primary end point was improvement in liver histology. Th e sample 
size calculation was based on an assumption that 30% improvement will 
be seen at liver histology in the combination group compared to UDCA 
alone. Using the α of 0.05 and 80% power a sample size of 80 patients 
allows suffi  cient power to detect a 30% improvement in liver histology. 
All data are expressed as mean ± SD. For comparison, the Student´s t-test 
and Mann-Whitney U-test were used. When variances were unequal, or 
their distribution was not normal, the Kruskal-Wallis multiple comparison 
test was used. A comparison of incidences was performed with χ2 statistics 
or Fisher´s exact test, and associations between the variables were tested 
by using the Pearson´s correlation coeffi  cient. Statistical calculations 
were performed with NCSS-2000 soft ware for Windows (NCSS Statistical 
Soft ware, Kaysville, UT) or with SPSS 13 soft ware for Windows (SPSS, Inc, 
Chicago, IL, USA). 
Th e study was approved by the Ethics Committee of the Helsinki 
University Hospital and the National Agency for Medicines. All patients 




5.1.1 Study population description
During the study period (1988–1999), the PBC population increased from 
294 to 545 patients. Th e characteristics of them are described in Study I, 
Table 1. Th e proportion of women  was rather stable, 85% to 87%, Th e 
diagnosis was defi nite for approximately 78% of the patients. Th e 22% of 
probable PBC diagnoses comprised AMA-negative patients (11%), those 
not confi rmed by liver biopsy (9%), and those with normal ALP (2%). 
Median age at diagnosis was 58 years in the beginning of the study 
and diminished a few years during the study period, but not signifi cantly, 
while the median age at death increased signifi cantly from 65 to 76 years 
(p = 0.001). Th e median time from diagnosis to death increased from 6 to 
11 years (p = 0.034) already aft er the fi rst three years and stayed stable the 
aft er that. 
5.1.2 Prevalence
In the beginning of the study, the overall age-standardized prevalence 
of PBC was 103 (95% CI 97 to110) per million inhabitants, increasing 
to 180 per million (172–189) by study end. In sex-specifi c analyses, the 
age-standardized prevalence in women was 161 (151–171) and increased 
to 292 (277–307) per million. In men, the prevalence increased from 33 
(28–38) to 55 (48–63).
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Figure 4. Point prevalence of PBC in 1999 in Finland (95% confi dence interval).
Th e point prevalence in 1999 in geographical areas is presented in Figure 
4. Th e prevalence tended to be lower in western Finland compared with 
the other areas, for both  women and men. Th e annual average increase 
in prevalence in the whole study area was 5.1% (p <0.0001); in the South 
5.1%, in the North 6.8%, in the Central Finland 4.1% (p <0.0001), and in 
the West 3.7% (p = 0.001). Prevalences are presented in three year periods 
in Figure 5. 
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Figure 5. Th e annual average incidence and prevalence of three year periods in the 
study area with 95% confi dence intervals. Incidence is presented per million per year 
and prevalence per million inhabitants.
5.1.3 Incidence
Th e mean age-standardized average incidence rates during the whole study 
period are presented by area in Figure 6. In western Finland the incidence 
tended to be lower than in other areas. When data on both sexes were 
combined, the diff erence between west and north became signifi cant, but 
otherwise no diff erences appeared between the study areas. During the 
study period the age-standardized incidence increased from 12 (10–14) to 
17 (15–20) per million annually. In women, the incidence increased from 
20 (16–24) to 27 (23–32) and in men from 3 (2–5) to 8 (6–11). Th e annual 
average increase in incidence in the whole study area was 3.5% (p = 0.008): 
in the South 4.2% (p = 0.04), the North 1.7%, the Central 3.2% and the 
West 5.2%, (p = ns). Th e annual average incidence in three year periods is 

















Figure 6. Mean age-standardized incidence of PBC in Finland 1988–1999(95% 
confi dence interval).
5.1.4 Mortality
During the study period (1988–1999) a total of 185 PBC patients died in 
the study area, over half (98) of them died of liver-related causes, including 
seven hepatocellular carcinomas (HCC), other causes consited of other 
malignancies (18), coronary heart disease (21), micellaneous causes (48). 
During the follow-up until 2004, 124 additional patients died, 54 of them 
for liver-related causes (10 HCC), other malignancies (11), coronary heart 
disease (16), and micellaneous causes (43). Death and transplantation rates 
per year and per PBC patient population are presented in Study I, Ttable 1. 
Approximately 4.2% of the patients died annually. 
5.1.5 Survival
Th e age, sex, and study area adjusted hazard ratio (HR) for all-cause deaths 
was 0.6 (0.4–0.9, p = 0.01) per 10-year increment in time, and HR for liver-
related deaths was 0.4 (0.2–0.8, p = 0.006) per 10-year increment. Survival 
in the four timepoints (1982–1999) of diagnosis for all-cause deaths and 
for liver-related deaths are shown in Figures 7a and b. Survival of this PBC 
population improved during the study years and follow-up period.
No signifi cant survival diff erences occurred between the study areas. 
Increasing age and male sex were signifi cantly associated with increasing 
risk of death: HR = 2.5 (2.1–2.9,  p <0.0001) per 10-years increment in age 
and HR = 1.6 (1.1–2.2, p = 0.009) for male sex. When liver-related deaths 
were used as the outcome, increasing age and early calendar time of the 
Mean incidence 1988-1999






per million per year
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PBC diagnosis signifi cantly increased the risk of death: HR = 2.1 (1.7–2.7, 
p <0.0001) and HR = 0.4 (0.2– 0.8, p = 0.006) per 10-year increment in age 
or in time of PBC diagnosis.






In all of Finland, 546 patient received their fi rst liver transplantation between 
1990 and 2006, and 85 (15.6%) of them were PBC patients. Th e relative 
amount of transplantations due to PBC decreased over time. In fi ve-year-
periods 1990–1994, 1995–1999, and 2000–2004 the PBC transplantations 
represented 25%, 19%, and 11% of all fi rst liver transplantations. From the 
study population 37 patients were graft ed for PBC during the study period 
1988–1999 and four patients before that (1985–1987). Th e overall liver 
transplantation rate from this PBC population was 5.4%.
5.2 Treatment study
5.2.1 Study population description
Th e baseline characteristics of 77 randomized patients appear in Table 3. 
Th e factors associated with osteoporosis, menopause, estrogen replacement 
therapy, smoking, and alcohol consumption, did not diff er between the 
groups. All patients were HBsAg and HVC-antibody negative. ANA 
positivity was found in approximately 7% of patients.
 Group A
Budesonide + UDCA 
Group B  
UDCA
Number (male) 41 (5) 36 (4) 
Age mean (range) 52.6 (33-67) 54.2 (25-70) 
BMI kg/m2  mean (range) 24.8 (18-38) 25.7 (20-30) 
Previous treatment with UDCA 32 28
Stage I (%) 13 (17) 13 (17) 
Stage II (%) 10 (13) 16 (21) 
Stage III (%) 18 (23) 7 (9) 
Grade 0 11 5 
Grade I 14 15 
Grade II 10 10 
Grade III 6 6
Fibrosis 0 13 13
Fibrosis I 11 16
Fibrosis II 11 6 
Fibrosis III 6 1 
Table 3. Baseline data of 77 randomized  patients.
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5.2.2 Biochemical markers
Table 4. Laboratory values at baseline and after 36 months. 
Th e values for ALP, ALT, GT, and AST improved in both groups (Table 4). 
A signifi cant statistical diff erence between groups appeared for bilirubin, 
AST, Alb, IgG, ESR, and PIIINP. Mean bilirubin levels were within normal 
limits in both groups, the levels stayed stable in group A (p = ns) and rose 
in group B (p = 0.01). Th e mean albumin and prealbumin levels remained 
unchanged in group A, whereas in group B the mean albumin rose (p = ns) 
and prealbumin decreased (p = 0.01), however, they remained within the 
normal range. S-IgG, ESR, and also a marker for fi brosis, PIIINP, decreased 
signifi cantly in group A. U-NTX showed no diff erence between groups, 
suggesting that bone resorption was not increased in group A. Th e only 
diff erence in biochemical markers of bone metabolism between the study 
groups (osteocalcin, PTH, Calcium, 25(OH)D3) was a signifi cant increase 
in vitamin-D in the group B (p < 0.05) (Study III, table 4).  Th e galactose 
elimination test, prothrombin time, and platelets remained stable in both 
groups, which were expected in non cirrhotic PBC. Th e mean levels of 
plasma cortisol decreased aft er 2 years in group A, demonstrating a slight 
systemic eff ect for budesonide (Study II, Figure 1). Glucose values did not 
riose compared to group B levels (Study II, Figure 1). 
Variables mean 




 0 months 36 months p value 0 months 36 months p value p value 
S-ALP, U/L 490 (313) 345 (210) 0.0002 516 (343) 388 (220) 0.02 ns 
S-Alt, U/L 64 (50) 40 (25) 0.0003 61 (40) 45 (25) 0.02 ns 
S-GT, U/L 203 (203) 107 (133) 0.0005 242 (297) 144 (296) 0.02 ns 
S-AST,  U/L 41.7 (46.0) 27.6 (15.9) <0.0001 46.0 (41.7) 31.7 (14.1) 0.03 0.048 
S-Alb, g/L 41.3 (2.9) 40.9 (2.3) ns 41.7 (2.7) 42.5 (2.8) ns 0.04 
S-Prealb mg/L 235 (49) 229 (57.5) ns 237 (41) 227 (42.3) 0.01 ns 
P-Prothrombin 
time, % 122.5 (26) 109.5 (45.5) ns 127.2 (28) 111.7 (36.4) ns ns 
B-Platelets, E9 /L   264 (56) 262 (66) ns 267 (108) 253 (94) ns ns 
S-Bil, mol/L 12.2 (4.7) 11.2 (4.0) ns 10.8 (4.4) 12.4 (4.8) 0.1 0.002 
S-IgM, g/L 3.4 (2.0) 2.3 (1.3) <0.0001 4.2 (2.6) 3.4 (2.5) 0.02 ns 
S-IgG, g/L 14.0 (3.3) 11.1 (2.1) <0.0001 13.4 (3.3) 12.5 (2.4) 0.01 0.0007 
B-ESR, mm/h 35 (21) 22 (14) <0.0001 32 (20) 29 (16) ns 0.02 




50.8 (38.4) 43.6 (21.3) ns 40.1 (20.6) 29.6 (15.2) 0.007 ns 




13 (6.4) 14 (5.0) ns 16 (4.7) 16 (6.5) ns ns 
Values are presented as means (±SD); p ≤ 0.05 considered signifi cant, ns : non signifi cant. 
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5.2.3 Doppler ultrasound and gastroscopy
No changes were detected at 36 months in the Doppler ultrasound or by 
upper endoscopy in any patient compared with baseline, except the one 
who developed hypocortisolism. She was dropped out of the study at 20 
months. Th e Doppler ultrasound demonstrated some minimal changes in 
her liver with no collaterals, but gastroscopy revealed grade-one varices 
(Study II).
5.2.4 Liver histology
Suffi  cient paired liver biopsies for analysis were available from 69 patients: 
37 patients in the combination group (A) and 32 in the UDCA group (B). 
In surrogate analysis the groups were not separated. Of liver biopsies 96% 
contained either >6 portal tracts or the length was ≥10mm. At baseline, 
more patients who were randomized into combination therapy already 
had stage III disease, 18 vs 7 at randomization and 15 vs 6 at analysis 
(p = 0.05). 
Th e improvement in liver histology was seen in group A in the stage 
(22%, p = 0.06), fi brosis (25%, p = 0.08), and grade (34%, p = 0.02), while 
the deterioritation of stage (20%, p = 0.07) and fi brosis (70%, p = 0.005) 
occurred in group B. Th e grade improved insignifi cantly in group B by 
10%. Th e signifi cant diff erences between the groups were found in the 
stage (p = 0.009) and fi brosis (p = 0.0009) in favor for the combination 
group (A), but not in the grade which was improved in both groups. Th e 
changes in grade consist of lobular hepatitis and interface hepatitis. Th e 
interface hepatitis improved in group A 42% (p = 0.006) and 8% (p = ns) in 
group B, no statistical diff erence between the groups appeared. Th e lobular 
hepatitis improved by 25% (p = ns) in group A and deteriorirated by 17% 
in group B (p = ns), no statistical diff erence existed between the groups.
Th e change in stage according to the baseline stage stratifi cation (Table 5) 
demonstrates the statistically signifi cant diff erence between the treatment 
arms only at stage II and at stages I and II combined. Th e histology in 8 
patients in the combination group improved towards normal, while no one 
reached normal histology in UDCA group (Table 5). Analyzing the stage 
by means of improvement/no change/worsening, the signifi cant positive 
eff ect in the combination group, compared with the UDCA group, is found 
in stages I and II separately and in all stages combined, but not in stage III 
separately. When the eff ect of the degree of grade on change of stage was 
analyzed, signifi cant diff erences between groups were found: if the grade 
was  ≥ 2, the stage improved signifi cantly in group A compared to UDCA 
alone, -0.67 vs 0.27, p < 0.01. If the  grade was ≤ 1, the  diff erence of the 
delta stage  did  not  reach statistically a signifi cant  diff erence (-0.27 vs 0.4 
in group A and B).
46
Table 5. Initial stage and consecutive stage after treatment in the combination group and in the 
UDCA group. When initial stages I and II are combined p = 0.04.
Consecutive stage 
Initial stage Budesonide and UDCA UDCA p
 0 I II III I II III  
I 2 5 5 0 3 6 2 ns 
II 4 2 2 2 5 3 7 0.04 
III 2 1 5 7 0 2 4 ns 
5.2.5 Pharmacokinetics of budesonide
Pharmacological measurements were analyzed from 22 patients of whom 
3 were in histological stage 0, 5 in stage I, 7 in stage II, and 7 in stage III at 
the time of analysis. Th e Cmax, AUC(0–24h), and t1/2 of budesonide did not 
diff er signifi cantly between the stages 0 and I combined, II, and III, Study 
III (Study III, Table 3). In those three patients with stage 0 the AUC(0–24h) 
seemed to be lower than in stages I–III, (Study III, Figure 1), but statistical 
analysis was not appropriate due to the small number of subjects in stage 0. 
No statistically signifi cant correlations between the Cmax, AUC(0–24h) or 
t1/2 of budesonide, and change of histological stage or grade, bilirubin level, 
or change of BMD were found.
5.2.6 Effects on bone
Analysis of the bone mass density (BMD) is based on 57 patients who 
did not receive bisphosphonates during the study and both paired liver 
histology and BMD measurements were available. 
Th e BMD in the baseline was slighty reduced in both groups compared 
with the normal population: the T-score in the femoral neck (FN) was 
-0.92 (SD 0.8) in group A and -0.94 (1.1) in group B and the T-score in the 
lumbar spine (LS) was -0.81 (0.96) and -0.76 (1.36).Th e mean BMD in the 
FN decreased during 3 years by 3.6% in group A (p= 0.0002) and by 1.9% in 
group B (p = 0.029). Th e reduction in BMD of the LS was 2.8% (p = 0.003) 
in group A and 0.7 % (p = 0.25) in group B. Th e diff erence in the reduction 
of BMD between groups, however, did not reach statistical signifi cance in 
FN (p = 0.16) or in LS (p = 0.08), (Study III, Figure 2). Th e changes of BMD 
in patients using budesonide did not correlate to the initial BMD, stage of 
liver disease, or tobacco smoking.
5.2.7 Adverse events
Two patients had major glucocorticoid dependent side-eff ects: in one 
patient the cortisol value decreased and the budesonide therapy was 
stopped (Study fl ow-chart fi gure 3), another patient had low cortisol values 
which normalized by reduction of the budesonide dose to 3 mg/day. Seven 
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patients reported mild glucocorticoid related side eff ects: bruises, thinning 
of skin, acne, nausea, mild hirsutism, and some weight gain (3 patients). 
None of these symptoms were severe requiring neither change in treatment 
nor in budesonide dose. Th e majority of the side-eff ects appeared in patients 
with stage III PBC (fi ve compared to two at earlier stages). In group B, two 
patients had itching related to elevation of UDCA dose. 
5.2.8 Biochemical markers and histology
Bilirubin and albumin levels were equal and normal in all stages. Th e AST, 
bile acids, PIIINP, and HA were statistically diff erent between the stages 
at baseline and at 36 months (except bile acids). Cholesterol precursors, 
cholestanol, campesterol, and sitosterol or their ratio did not diff er between 
the stages.
Th e PBC-score, combination of HA, PIIINP, bile acids, and AST 
demonstrated the best correlation with the diff erent stages (p < 0.0001), 
Table 6. Logarithmic(ln) transformation of individual variables of the 
score improved discrimination value of ANOVA, p-value for the lnPBC-
score was 0.00002. Th e discriminant function for variables of lnPBC-score 
for stage is: -1.56*ln(AST) – 0.71*ln(HA) – 0.10*ln(PIIINP) -0.55*ln(BA) 
+ 7.85, p = 0.009. Of other calculated scores only the AST/platelet ratio 
index (APRI) demonstrated a signifi cant association between the stages 
both at baseline and aft er 36 months of therapy. Th e ALT/AST-ratio did 
not detect diff erent stages, neither could the Forn’s index nor Fibrosis index 
diff erentiate the stages at baseline. 
Th e grade of lymphocytic piecemeal necrosis (LPN) was classifi ed as 
dichotomic variable as follows: none to mild infl ammation (0–1) and 
moderate to severe (2–3). At baseline the serum levels of ALP, IgG, HA, 
and PIIINP demonstrated a signifi cant diff erence between mild and severe 
LPN. Only PIIINP was constantly associated with the degree of LPN. 
Th e scores for APRI, ALT/platelet, PBC-score, and campe/sito-ratio were 
statistically diff erent between groups at baseline. Th e discriminant function 
for variables of lnPBC-score for LPN is: 1.21*ln(AST)+ 0.56*ln(HA)+ 
074*ln(PIIINP)+ 0.26*ln(BA)-7.81, p = 0.020.
Fibrosis was scored to none or minimal fi brosis (F0-1) or increased 
fi brosis (F2-3). Of the laboratory parameters only AST, HA, and PIIINP 
were signifi cantly associated with degree of fi brosis, both at baseline and at 
36 months. From the scores, only APRI and PBC-score were signifi cantly 
diff erent between F0-1 and F2-3. Th e discriminant function for variables of 
LnPBC-score for fi brosis is: 0.69*ln(AST) + 0.24*ln(HA) + 1.53*ln(PIIINP) 
+ 0.59*ln(BA)-6.77, p = 0.026.  
We were unable to fi nd any association between the changes of HA, 
PIIINP, bile acids, or their sum (PBC-score), and the change of the 
stage, degree of fi brosis, or grade. Only the changes in Forn’s score were 
signifi cantly diff erent (ANOVA) in patients with improvement or no 
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change in stage compared to those with worsening of the stage and the 
change of campe- and sitosterol revealed association with the change of 
fi brosis graded accordingly (data not shown).
5.2.9 Sensitivity and specifi city of biochemical markers
The correlation of HA with stage and the METAVIR fi brosis score at baseline 
was rs = 0.356 and rf = 0.322. The respective correlations for PIIINP were 
rs = 0.384 and rf  = 0.410, for APRI rs  = 0.338 and rf  = 0.262, for PBC-score 
rs = 0.513, rf = 0.481. Areas under the ROC curves (AUROC) were used 
to evaluate the sensitivity and specifi city of biochemical parameters and 
the calculated scores. The PBC-score demonstrated the highest value for 
AUROC for stage 0–1 vs stage 2–3, both at baseline and after 36 months. 
AUROC was 0.785 for the PBC-score, 0.673 for HA, 0.660 for PIIINP, and 
0.720 for AST. Using a cut-off value of 66 for the PBC-score the sensitivity 
was 81.4% and specifi city 65.2% for classifying the stage of PBC. Dropping 
the cut-off value to 57 the sensitivity increased to 86.0% and specifi city 
dropped to 40.0 %. For fi brosis, all the biochemical variables and calculated 
scores were less sensitive. S-AST and the PBC-score were the most sensitive 
parameters to evaluate the grade of LPN.
Stage 0-1 vs 2 vs3 LPN 0-1 vs LPN  2-3 F 0-1 vs F 2-3 Variable 
Baseline 36 mo Baseline 36 mo Baseline 36 months 
B-platelets NS NS NS NS NS NS 
S-bilirubin NS NS NS NS NS NS 
S-AST <0.05 <0.05 NS NS <0.05 <0.05 
S-ALT NS <0.05 NS NS NS <0.05 
S-ALP NS <0.05 <0.05 NS NS NS 
S-gGT NS NS <0.01 NS NS <0.05 
S-IgM NS NS <0.05 <0.01 NS NS 
S-IgG NS NS NS <0.05 NS <0.01 
S-bile acids <0.05 NS NS NS <0.05 NS 
S-HA <0.05 <0.01 <0.05 NS <0.01 <0.01 
S-PIIINP  <0.01 <0.01 <0.01 <0.01 <0.01 <0.05 
S-Cholesterol NS NS NS NS NS NS 
S-Cholestanol, NS 0.05 NS NS NS <0.05 
S-Sitosterol NS NS NS NS NS NS 
S-Campesterol NS NS NS NS NS NS 
APRI <0.01 <0.05 <0.05 NS <0.05 <0.05 
ALT/platelet NS <0.05 <0.05 NS NS <0.05 
AST/ ALT NS NS NS NS NS NS 
Fibrosis index NS <0.05 NS NS NS <0.05 
Forn’s NS NS NS NS NS NS 
PBC-score <0.0001 <0.01 <0.01 NS <0.001 <0.01 
Campe/sito NS NS <0.05 NS NS NS 
Table 6. The P value of biochemical markers and serological scores according to the histological 
stage, lymphocytic piecemeal necrosis (LPN), and fi brosis (F) at baseline and at 36 months
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6 DISCUSSION
6.1 Epidemiology of PBC
Th e prevalence and incidence of PBC are increasing in the western world. 
Almost every prevalence data from North America or Europe collected 
aft er 1994 are higher than data collected before that year (Figure 1). Th e 
same trend is also seen in the incidence, though not as clear as in prevalence. 
Th e USA (52) and UK (54) are the most prevalent places of PBC in the 
world and high numbers from the UK were already reported at 1980s. 
Our data showed a marked annual increase both in prevalence (5.1%) and 
in incidence (3.5%) over 12 years time period in Finland (Study I). Th e 
Finnish epidemiological data are comparable to the Swedish (49,50,55) 
and Norwegian ones (56), but Nordic prevalence and incidence numbers 
are still far from the USA and UK. Th e diff erences within geographical 
areas studied in Finland were small, though the western Finland showed a 
lower prevalence than the rest of Finland (Figure 4). Th e incidence in the 
west was also lower than in Northern Finland, but not diff erent compared 
with the other parts of Finland (Figure 6). Th e reasons for these lower 
numbers in western Finland are diffi  cult to fi nd, the health care system 
should be equal in diff erent parts of Finland. One possible explanation for 
the higher prevalence in the north is the migration of young women to the 
southern parts of Finland, leaving the rapidly increasing prevalence in the 
north while new diagnosis of PBC are made more in the southern parts of 
Finland leading to the increasing incidence in the south.
Some of the increase might be explained by better awareness of the 
disease and active use of laboratory tests in occupational health care in 
non-symptomatic patients. Th is, however, can not explain everything. Th e 
age of the patients having a new diagnosis did not markedly decrease in 12 
years in the study population. Mitochondrial antibodies are very specifi c 
for PBC and have already been used for four decades, so the diagnosis 
is easy to make with biochemistry and confi rmation with histology is 
optional. In our study (I), we accepted both defi ned and propable diagnosis 
to prevalence and incidence numbers, as have also other surveys done, and 
the proportion of defi nite diagnosis during the study period was stable (in 
three years periods 80%, 78%, 80%, 80%), which supports the idea that 
an enhanced diagnostic work up is not the main reason for the increased 
prevalence and incidence of the PBC. 
50
Th e improved overall survival was also confi rmed in the Finnish 
population: 40% survival improvement in all deaths and 60% for liver 
related deaths per 10-year time increment. Th is obviously explains part of 
the increasing prevalence. Also, the excellent results of liver transplantations 
decrease the mortality of these patients. In Finland, at 1, 5, and 10 years 
aft er transplantation the PBC survival was approximately 95%, 88%, and 
77% (Personal information. Isoniemi H, 2007). For comparison the survival 
in Birgmingham transplantion unit was 82%, 75%, and 61% (158). Th e 
transplantation itself does not cure PBC and recent publications show that 
the recurrence of PBC in liver allograft  occurs in approximately 18% of the 
patients (159). Th e recurrence of disease seldom causes loss of the allograft .
Enviromental factors may explain the increase in PBC incidence. 
Novosfi ngobium aromaticivorans, a gram negative bacterium, which 
has the highest level of homology between any known microorganism 
and human PDC-E2, can metabolize xenobiotics and give a start to the 
autoimmune process leading to infl ammation and destruction of bile ducts 
(40). With our modern lifestyle we are increasingly exposed to chemicals 
in our everyday life. Studies show that smoking, hair dye (44), nail polish 
(167), lipsticks, detergents, food fl avorings (46), and livingplaces near 
superfund toxic waste (45) are risk factors for PBC.
6.2 Prognosis and treatment of PBC
Th e survival of PBC has markedly improved since the 1980s and the 
mostly used Mayo prognostic curve (99), made before UDCA treatment, 
no longer applies to the PBC population of today. Its value is limited in 
showing how the patients would do without any treatment and serves as 
a control prognostic model. It seems probable that UDCA has a positive 
eff ect on survival, even though it is not shown in meta-analyses (118,119). 
Th e reduction of need for liver transplantations with UDCA treatment was 
found in a Chinese meta-analysis of 7 randomized conrolled trials (RTC) 
(118), but not in the meta-analysis of 15 RTCs (119). Recent studies from 
Holland (121) and Spain (122) show that patients with normal bilirubin 
and albumin levels on UDCA treatment have the same survival expectation 
as the normal population. It has also been shown that histological stage is a 
good prognostic factor for survival (120). Th e signifi cant positive eff ect of 
UDCA has been shown in liver histology in the early stages of PBC, but not 
in the later stages (120,117). Th is fi nding was not confi rmed in the latest 
meta-analysis (119).  Th e UDCA treatment, however, does not stop the 
disease progression in all patients. At least 50% of patients even in the early 
stages (120), if not dead earlier for other reasons, will end up with liver 
cirrhosis and eventually suff er from decompensation or complications of 
cirrhosis. Today, the only approved medical therapy for PBC is UDCA, 
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although its positition is challenged with the recent meta-analysis, and 
novel therapies should come on top of it. 
Immunosuppressive and immunomodulatory medications have been 
studied in PBC, but none of them have been superior to UDCA. Th is was 
found also in a Finnish study comparing UDCA with colchicine or placebo 
(168). Individual patients may benefi t from additional colchicine (169), 
but the meta-analyze did not confi rm its eff ect (135).
Corticosteroids have been shown to improve liver histology (123–125). 
Prednisolone has systemic side-eff ects and especially bone mass density 
may decrease (123). Budesonide with its high fi rst pass metabolism in the 
liver (127) gives the opportunity to treat the liver infl ammation with less 
systemic eff ects. Th e budesonide 9 mg/day in combination with UDCA has 
been shown to improve liver histology by 30% in two years of treatment 
compared to UDCA alone, where the histology deteriorated by 3.5% 
(126). Th e eff ect on infl ammation was clear, a 25% improvement in the 
combination group compared to a 3.2% improvement in UDCA treatment. 
In our study (II), we combined UDCA to a lower dose of budesonide, 
6 mg/day, for three years and found a 22% improvement of stage in the 
combination group and 20% deterioration of stage in UDCA group. Th e 
number of patients whose stage improved or remained stable was 30/37 in 
the combination group and 17/32 in the UDCA group. If only improvement 
is considered the numbers were 16/37 and 7/32. Eight patients in the 
combination therapy group normalized their liver histology in three years 
while none of the UDCA group had such a marked improvement. Th e 
number of patients evaluated was 69, not 80 as planned, but the changes 
in the histology were stronger than expected so the power in our study 
remined strong. Th e improvement of the histological stage really is there, 
whether you evaluate the eff ect in an individual patient or the overall 
improvement in a group of patients. 
Who of the patients would benefi t from the combination therapy? Th e 
age at onset of PBC varies, certainly the overall impact of PBC is larger 
to a patient at 25 years compared with a patient over 70. Th e treatment 
activity should be individual. Th e treatment of PBC should always start 
with UDCA, but if the biochemical eff ect is not full the prognosis is worse 
in these patients compared to patients with a full biochemical response, 
and probably normal survival (121, 122). In our study (II), the histological 
infl ammation was a prognostic factor for improvement of stage. If the 
grade was ≥ 2, the eff ect on the stage was larger than if the infl ammation 
was mild, grade ≤ 1. In case of a partial or no response to UDCA the liver 
biopsy should be considered and if the infl ammation is found, despite the 
UDCA treatment, then additional medications should be introduced. An 
interesting issue is the duration of the additional treatment. Would a short 
(1–2 years) induction therapy with budesonide be enough or do these 
patients need maintenance therapy with budesonide?
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6.3 Safety of the budesonide
6.3.1 Pharmacokinetics
Th e safety aspects of corticosteroid therapy, even with budesonide, are 
a concern. Budesonide has a high fi rst pass metabolism in the liver and 
liver diseases aff ect the metabolism (170). Th e patients with advanced 
liver disease, cirrhosis, are no longer candidates for budesonide therapy 
(170). Th e pharmacokinetics of budesonide have been previously studied 
in short-term studies (from single dose to three weeks) in PBC-patients, 
and there seems to be a marked diff erence between the early stage (I–II) 
PBC and the cirrhotic stage (IV). Patients with cirrhotic PBC have about 
3–4 times higher plasma budesonide concentrations than patients with 
early stage PBC (170). In our study with 22 patients (III), no diff erences 
were observed in the AUC of budesonide in stages 0–I, II, and III. Th e 
pharmacokinetics of the three patients at stage 0 actually seemed similar 
to what would be expected with the present dosing in healthy subjects on 
the basis of a previous study about the single-dose pharmacokinetics of 
budesonide (171). In their study, the AUC and Cmax were higher in patients 
with early stage PBC than in healthy volunteers aft er a single dose of 3 
mg budesonide (171). Th e small number of patients at stage 0 limited our 
possibility to fi nd a statistical diff erence compared to other groups. In 
our study (III), the systemic eff ect of budesonide in patients with stages 
I-III was seen aft er two years when the serum cortisol levels started to be 
lower in the combination group compared to patients on UDCA alone. 
A clinical concern of long term use of budesonide is its metabolization 
by cytochrome P450. Th e coadministration of budesonide and CYP3A4 
inhibitors, for example antifungal itraconazole, markedly increases the 
systemic exposure to budesonide and may lead to an increased risk to 
adverse eff ects (172).
6.3.2 Effects on bone
Osteoporosis and osteopenia in PBC have been an issue of controversy. It 
seems that PBC patients have more osteoporosis than general population, 
but does the stage of PBC associate with osteoporosis remains controversial. 
In an American study the rate of osteoporosis was 32.1 times higher in PBC 
patients than expected and the risk was 5.4 fold in patients at stages III and 
IV compared to stages I and II (138).  In their study other independent 
risk factors were age, body mass index, and a history of fractures. Th e 
Spanish study found an increase of osteoporosis in PBC patients to be 
associated with age, menopausal status, BMI, and duration of PBC, but 
also with advanced histological stage and abnormal biochemistry (139). 
In the French study the PBC patients had a Z-score of -0.9 SD, meaning 
a lower BMD than the control population, however, they did not fi nd an 
association with stage in liver histology. In their study population the only 
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risk factor was hormonal status. Th e T-score was -1 SD in premenopausal 
women, -1.1 SD in postmenopausal women with hormonal replacement 
therapy, and -2.7 SD in postmenopausal women without replacement 
therapy (140). Th e American gastroenterological association found 
level A evidence to support the view that the PBC patients are at risk for 
osteoporosis and fractures due to predominant female sex and older age, 
but not due to cholestatic liver disease per se (173) . In a population based 
study from the UK, the risk for any fractures in PBC patients was a 2-fold 
increased compared to the general population (141). Th e histological stage 
had no eff ect on fracture rates. In our PBC population (Studies II and III), 
the baseline bone mass density was not signifi cantly associated with the 
baseline stage of PBC, but the result refers to a rather mild PBC with a 
small number of patients at stage III and no patients at cirrhosis. 
Th e fracture risk in the post orthotopic liver transplantation (OLT) 
period is high and the single most important risk factor is the pre OLT 
osteopenia (173). Bearing this in mind the treatment with budesonide 
should be extremely safe in regards to BMD. In our study (III), despite 
calcium and vitamin-D supplementation, bone mass density decreased 
in the combination therapy (FN 3.6% and LS 2.8%) somewhat more than 
in UDCA monotherapy (FN 1.9% and LS 0.7%), although the diff erence 
between the groups was not statistically signifi cant. Th e greatest BMD 
reduction usually occurs during the fi rst months of the glucocorticoid 
therapy (174), and our long-term therapy might alleviate the early 
diff erences between the treatment groups. 
A considerable scattering exists in the eff ects of both treatments on 
the BMD values both in the FN and LS. Th e fi nding that three of the 32 
patients of the budesonide-UDCA group had a 10% or greater decrease in 
the femoral neck BMD within 3 years is of concern. Only one of the patients 
using UDCA alone had an over 10% decrease in BMD. Th e situation in 
LS was better. Only one patient in the combination group had a decrease 
over 10% in BMD, and clinical fractures in post-OLT situation are more 
common in LS. Unfortunately, neither the BMD at the entry nor the stage 
of PBC was able to predict those patients who developed the greatest BMD 
changes. Th e number of patients with a bone density analysis in our study 
III was only 57, which may be inadequate to fi nd associations between the 
BMD and the above mentioned predicting factors. Th e study with 9 mg/
day of budesonide for two years (126), showed reductions of BMD in LS 
of 2.3% in the combination group and 1.2% in the UDCA group (they 
did not provide data on FN) and compared with our budesonide group 
their reductions were slightly smaller. Angulo et al. treated 22 patients 
with a combination of UDCA and budesonide, 9 mg, for one year in an 
open not randomized study and compared the bone density before and 
aft er the treatment and with matched controls (131). Th ey found a marked 
decrease of BMD in the treatment group compared to matched controls, 
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and the loss of bone density was greater in cirrhotic patients compared 
to non-cirrhotics, and postmenopausal compared to premenopausal 
women (131). Th is study shows how important the patient selection to 
the individual treatments is. We know now that the cirrhotic patients 
are no longer candidates for budesonide therapy (170). Postmenopausal 
women are at a greater risk for osteoporosis even without liver disease 
or the use of budesonide. Th e transdermal estrogen therapy is shown to 
be eff ective in increasing BMD (142,143), and safe in regards to the liver 
(142), in postmenopausal PBC patients. Th e estrogen replacement therapy 
is recommended in early menopause and female hypogonadism, but not in 
older postmenopausal women (137). Th e hypogonadism of men should be 
treated with testosterone (137).
Th e possibility of making budesonide treatment even safer is to limit 
its use to men and premenopausal women, although that would raise the 
question of not having alternative therapies for others. Careful screening 
and follow up for osteoporosis is essential in PBC patients, especially for 
those whose liver disease is not stable and the need for additional therapies 
and even OLT exists. Th e treatment options for osteoporosis with life style 
changes (smoking, exercise, and calcium and vitamin-D supplementation) 
include raloxifene, calcitonin, and PTH (137). In recent years the studies 
with alendronate have shown improvement in BMD (145) and it seems 
superior to etindronate in patients with PBC (144). Short term safety is 
good, but long term safety data on PBC patients is lacking.
6.4 Liver transplantation and complications of cirrhosis
PBC has been the foremost indication of liver transplantation in Finland. 
By the end of 2006, 106 patients were graft ed for PBC.  Diff erences in causes 
of OLT between the Nordic countries exist. Th e proportion of PBC/alcohol 
cirrhosis/viral cirrhosis (HBV and HCV) were 11.9/13.8/3.2% in Finland, 
8.3/24.3/5.3% in Denmark, 5.5/18/13.3% in Norway, and 6.6/10.2/21.1% in 
Sweden during the period from 1997 to 2005 (www.scandiatransplant.org). 
If only percentages of liver transplantations for PBC are evaluated, the Finnish 
transplantation rates for PBC may seem high compared to the other Nordic 
countries.  Th e high percentage of PBC transplantations in Finland, however, 
is only relative because of low numbers of alcohol and viral cirrhotic patients 
in our liver transplantation population.  Th e fi nding is comparable with data 
form the European Liver Transplant Registry (www.eltr.org), from 1988 to 
the end of 2005, 11% of transplantations was performed for PBC, 33% for 
alcohol cirrhosis, and 41% for viral cirrhosis. Th e Finnish transplantation 
numbers at the same time were 18%, 10%, and 2%. 
Th e hepatocellular carcinoma may aff ect the survival of PBC patients. 
Th e risk for HCC is reported to be as high as 12.3% in stages III and IV PBC 
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(97). We have no data on prevalence of HCC in PBC in Finland, but it was 
also a marked cause of death in our epidemiological study (I) population: 
309 patients died, 152 (49%) for liver related reasons, and 17 of them, 6%, 
from all deaths for HCC. Th e surveillance for HCC in autoimmune based 
cirrhotic patients should be considered.
Portal hypertension with esophageal varices is common in the late stages 
of PBC, however, some patients may already develop varices at early stages. 
Th e regular gastroscopy screening for varices gives opportunity to treat 
them early with either medication (propranolol) or with the rubberband 
ligation. Th e ascites formation usually occurs late in the cirrhosis of PBC 
and the patients require consideration for liver transplantation.
In addition to liver transplantation, the possibilities to improve the 
survival in PBC are the early diagnosis and active medical treatment at 
early stages when changes in the liver are still recoverable. Stage IV is 
already beyond medical therapy, stage III is beyond UDCA therapy and 
the risks for the budesonide therapy are increased. Th e optimal timing 
for medical therapy is at stages I and II. Th e majority of the PBC patients 
have a positive or at least stabilizing eff ect of the UDCA therapy on the 
histology. Additional medications, however, are required for UDCA non-
responders.  Our current knowledge of the positive eff ect of budesonide 
in PBC is based on the precirrhotic PBC patients on UDCA therapy, 
not especially for UDCA non-responders. Th e further studies should be 
focused on the UDCA non-responders in order to fi nd the real additional 
benefi t of budesonide.
6.5 Surrogate markers of PBC
Th e possibility to treat patients with medical therapy results to the desire 
to fi nd out the progression of PBC already at the early stages, not only 
to fi nd out when patients reach cirrhosis. Liver histology has been the 
gold standard for evaluating the stage, infl ammation, and fi brosis in PBC. 
Liver biopsy, however, is costly, uncomfortable for the patient, has safety 
risks, and is prone to sampling errors. Th ese matters have raised a need for 
surrogate markers determining progression of PBC. 
So far surrogate marker studies in liver diseases have mainly concentrated 
on common diseases, like viral- and non-alcoholic steatohepatitis. In those 
numerous studies it seems clear that the cirrhotic phase and non-cirrhotic 
phase of the diseases are rather easy to distinguish with biochemistry, but 
there is a marked overlapping in surrogate markers within diff erent non-
cirrhotic phases (175–177).
Th e combination of age, HA, PIIINP, and TIMP1 (tissue inhibitor of 
matrix metalloproteinase 1) excluded fi brosis with an accuracy of 92% 
with ROC 0.804 (178), this study also included patients with cholestatic 
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liver diseases. Grading infl ammation in PBC with surrogate markers have 
not been as succesfull, however, AST may have some value (166). 
In our study (IV), with non-cirrhotic patients the main fi nding was that 
most of the biochemical parameters, routinely used in clinical work, do 
not actually correlate with the stage, fi brosis, or the infl ammation. Only the 
AST activity turned out to be associated with the stage and the degree of 
fi brosis. Both HA and PIIINP levels were better in separating the diff erent 
stages and fi brosis scores. Th e sumcombination of these parameters (AST, 
HA, PIIINP, and bile acids), the PBC-score, increased the diff erentiating 
cabability between the non-cirrhotic stages and the scores of fi brosis up to 
a highly signifi cant level (p < 0.0001).
Th e PIIINP was constantly associated with the level of LPN, ALT, and 
GT were associated at baseline, but we could not fi nd correlation of the 
AST- level and the degree of LPN previously suggested by Corpechot (166), 
however, the AUROC for AST to detect signifi cant LPN was 0.746, which 
has clinical value. Th e ALT/platelet ratio and the APRI as well as the PBC-
score were associated at baseline.
Bilirubin is a strong prognostic factor when evaluating the need for 
liver transplantation in PBC, but in our precirrhotic material it does not 
have a role as a surrogate marker. Bilirubin levels were equal and normal 
in diff erent stages. Compared to bilirubin, the increase of bile acids is a 
more sensitive marker of cholestasis and it showed correlation between 
the diff erent stages and scores of fi brosis in baseline measurements in our 
study (IV).
Plantsterols and cholestanol did not refl ect the stage of PBC or the 
amount of fi brosis in this study. Previously they have been reported to 
correlate with bilirubin levels in PBC (179), but in precirrhotic stages they 
do not seem to give additional information.
Comparison of AUROCs between biochemical variables and scores 
for discriminating the stages, fi brosis, and LPN, the PBC-score and the 
discriminant function of the PBC-score were superior in the stage, fi brosis, 
and LPN compared with previously reported scores. Using a cut-off  value 
of 66, the sensitivity was 81.4% and specifi city 65.2% for classifying the 
stage of PBC. 
Th e specifi c value of the surrogate markers will grow as they and 
their combinations are examined thoroughly. Already with the present 
information we may start to use markers in monitoring therapies, aiming 
to reduce the number of repeated liver biopsies. Th e markers could also 




Th e prevalence and incidence of PBC are increasing in Finland along 
with the other western countries. Th e increased incidence is partly due to 
a better awareness of PBC and an expanded use of routine biochemistry 
measurements in occupational health care, but probably also the increasing 
exposure to the chemicals in our everyday life has an impact in introducing 
antigens to suspectible individuals. Together the increasing incidence and 
the improved survival explain the increase in prevalence. 
In planning the treatment, the overall suspected eff ect of PBC on 
an individual is important. Th e age at onset of the disease, the disease 
severity, the grade of infl ammation, and the response to UDCA therapy 
are the key issues. Th e diagnosis should be made at an early stage of the 
disease to be able to treat the infl ammation and stop the progression 
of fi brosis. Th e initial treatment is UDCA, but for the UDCA non-
responders the additional therapy with budesonide should be introduced. 
Th e combination of budesonide and UDCA is superior in stabilizing, or 
even reversing, the stage of PBC compared to UDCA alone. Th e safety 
evaluation of budesonide treatment is essential.Th e adrenal suppression, 
hyperglycemia, and reduction of BMD may occur. Th e medical therapy is 
limited to the precirrhotic stages of PBC and the liver transplantation is the 
only treatment option in cirrhosis, however, the need for transplantations 
is reducing in PBC. Th e transplantation results are excellent, a 95% survival 
rate aft er one year and 77% aft er 10 years.
Hyaluronic acid, PIIINP, AST, and bile acids may serve as surrogate 
markers to monitor the treament response in the early stages of PBC. 
Combining these biomarkers in to a simple index may potentiate their 
diagnostic value and give possibilities to reduce repeated liver biopsies in 
patient follow up. 
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